

XERMELO[®] Patient Registry: A Real-World Evidence Study Evaluating Patient-Reported Outcomes with XERMELO

TAP TO GO BACK TO KIOSK MENU

Vijay N. Joish¹, Mark A. Price², Steven Schwartz³, Shanna Jackson¹, Lee Bennett², Christina Darden², Eshetu Tesfaye¹, Quintellia Mobley³, Karie Arnold¹, Suman Wason¹, Pablo Lapuerta¹

¹Lexicon Pharmaceuticals, Inc., The Woodlands, TX, USA; ²RTI Health Solutions, Research Triangle Park, NC, USA; ³Envoy Health, Flint, MI, USA.



Full ePoster

Table

Figure 1

Figure 2

Table. Baseline characteristics of participants in the RELAX registry

Characteristic	Baseline (N = 56)
Age, mean (SD)	62 (11.5)
Female sex, n (%)	34 (60.7)
Weight, mean (SD), kg	82 (26.2)
Race or ethnicity, n (%)	
White or Caucasian	47 (83.9)
Black or African-American	7 (12.5)
Hispanic or Latino	1 (1.8)
Native Hawaiian or other Pacific Islander	1 (1.8)
Region, n (%)	
Northeast	10 (17.9)
Midwest	11 (19.6)
South	25 (44.6)
West	10 (17.9)

Characteristic	Baseline (N = 56)
Site of primary NET, n (%)	
Small intestine	38 (67.9)
Appendix	1 (1.8)
Other	14 (25.0)
I don't know/don't remember	3 (5.4)
Time from NET diagnosis to baseline, mean (SD), years	5.5 (4.1)
Time from CS diagnosis to baseline, mean (SD), years	5.5 (4.3)
Surgery for CS in the past 6 months, n (%)	7 (12.5)
Additional treatment for CS in the past 6 months, n (%)	13 (23.2)
SSA treatment for CS symptoms in the past 1 month, n (%)	
Rescue medication (short-acting SSA)	13 (23.2)
Monthly long-acting SSA injection	55 (98.2)

SD, standard deviation; NET, neuroendocrine tumor; CS, carcinoid syndrome; SSA, somatostatin analog

XERMELO[®] Patient Registry: A Real-World Evidence Study Evaluating Patient-Reported Outcomes with XERMELO

TAP TO GO BACK TO KIOSK MENU

Vijay N. Joish¹, Mark A. Price², Steven Schwartz³, Shanna Jackson¹, Lee Bennett², Christina Darden², Eshetu Tesfaye¹, Quintellia Mobley³, Karie Arnold¹, Suman Wason¹, Pablo Lapuerta¹

¹Lexicon Pharmaceuticals, Inc., The Woodlands, TX, USA; ²RTI Health Solutions, Research Triangle Park, NC, USA; ³Envoy Health, Flint, MI, USA.



Full ePoster

Table

Figure 1

Figure 2

Figure 1. Patient satisfaction with control of CS symptoms at baseline and after 6 months



CS, carcinoid syndrome; TE, telotristat ethyl.

XERMELO[®] Patient Registry: A Real-World Evidence Study Evaluating Patient-Reported Outcomes with XERMELO

TAP TO GO BACK TO KIOSK MENU

Vijay N. Joish¹, Mark A. Price², Steven Schwartz³, Shanna Jackson¹, Lee Bennett², Christina Darden², Eshetu Tesfaye¹, Quintellia Mobley³, Karie Arnold¹, Suman Wason¹, Pablo Lapuerta¹

¹Lexicon Pharmaceuticals, Inc., The Woodlands, TX, USA; ²RTI Health Solutions, Research Triangle Park, NC, USA; ³Envoy Health, Flint, MI, USA.



Full ePoster

Table

Figure 1

Figure 2

Figure 2. Global Impression of Change at Month 6

